Cancer immunotherapy developer IRX Therapeutics has appointed Mark Leuchtenberger president and CEO. John Hadden, founder and prior CEO of New York-based IRX, will remain a director of the company.
Leuchtenberger’s experience includes executive and senior management positions at Chiasma (NASDAQ: CHMA), Acusphere, Rib-X Pharmaceuticals, Therion Biologics, and Biogen (NASDAQ: BIIB). IRX also named Monil Shah chief operating officer. Shah was most recently medical affairs lead for immuno-oncology at Bristol-Myers Squibb (NYSE: BMY).